Breaking News, Collaborations & Alliances

ABL Bio and GSK to Develop Medicines for Neurodegenerative Diseases

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

By: Rachel Klemovitch

Assistant Editor

ABL Bio, a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, entered a worldwide licensing agreement enabling GSK to develop medicines for neurodegenerative diseases by utilizing ABL Bio’s blood-brain barrier (BBB) shuttle platform, Grabody-B.  The agreement aims to develop multiple programs for targets across therapeutic modalities including antibody, polynucleotide, or oligonucleotides, such as siRNA and ASOs, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters